The Next Drugs: The Future for Biosimilars
An Atlantic Policy Briefing

March 15, 2017
Washington, DC

New guidelines on naming and interchangeability from the Food and Drug Administration point to a changing role for biosimilars, while some of the Trump Administration's policy priorities, if implemented, could alter the dimensions of the American market.

The Atlantic gathered key stakeholders to examine the future for biosimilars domestically and abroad. What impact will the President's policies have on the industry? Will changes in regulation affect how many biosimilars are approved, and what impact will these have on ensuring that these drugs are safe and accessible for the patients who need them?


Watch full session videos

Presented by

Atlantic Live

Speakers

Agenda

  • Wednesday, March 15
  • 8:15 a.m.WelcomeMargaret Low, President, AtlanticLIVE
    Chester “Chip” Davis, Jr., President and Chief Executive Officer, Association for
    Accessible Medicines
  • 8:20 a.m.An Update from Capitol HillRepresentative Michael Burgess, MD (R-TX)
    With Joie Chen, Journalist and Contributor, AtlanticLIVE
  • 8:45 a.m.What the New Rules MeanJim Van Lieshout, Vice President, Market Access and Pharmacy Strategy, Apobiologix
    Len Lichtenfeld, MD, Deputy Chief Medical Officer, American Cancer Society
    David Fox, Partner, Hogan Lovells
    With Joie Chen, AtlanticLIVE
  • 9:15 a.m.ClosingMargaret Low, AtlanticLIVE

Underwriter

Also in This Series

Upcoming Events